Effect of intensive insulin therapy on the somatotropic axis of critically ill children.

CONTEXT Intensive insulin therapy (IIT) improved outcome in the adult and pediatric intensive care unit (PICU) compared with conventional insulin therapy (CIT). IIT did not increase the anabolic hormone IGF-I in critically ill adults, but feeding in critically ill children and pediatric hormonal responses may differ. Twenty-five percent of the children with IIT experienced hypoglycemia, which may have evoked counterregulatory responses. OBJECTIVE We hypothesized that IIT reactivates the somatotropic axis and anabolism in PICU patients. DESIGN This was a preplanned subanalysis of a randomized controlled trial on IIT. PATIENTS We studied 369 patients who stayed in PICU for at least 3 d (study 1) and 126 patients in a nested case-control study (study 2). MAIN OUTCOME MEASURES Circulating insulin, C-peptide, GH, IGF-I, bioavailable IGF-I, IGF-binding protein (IGFBP)-1, IGFBP-3, and acid-labile subunit were analyzed upon admission and d 3. In the nested case-control study, the somatotropic axis, cortisol, and glucagon were analyzed before and after hypoglycemia. RESULTS On d 3, C-peptide was more than 10-fold lower (P < 0.0001) in the IIT group than in the CIT group. IIT increased circulating GH (P = 0.04) and lowered bioavailable IGF-I (P = 0.002). IIT also decreased IGFBP-3 (P = 0.0005) and acid-labile subunit (P = 0.007), while increasing IGFBP-1 (P = 0.04) and the urea/creatinine ratio, a marker of catabolism (P = 0.03). In the nested case-control study, IGFBP-1 was increased after hypoglycemia, whereas the somatotropic axis and the counterregulatory hormones cortisol and glucagon did not change. CONCLUSIONS Despite improved PICU outcome, IIT did not counteract the catabolic state of critical illness. Suppression of portal insulin may have resulted in lower bioavailable IGF-I.

[1]  G. Van den Berghe,et al.  Glucose dysregulation and neurological injury biomarkers in critically ill children. , 2010, The Journal of clinical endocrinology and metabolism.

[2]  D. Chinkes,et al.  Intensive insulin therapy improves insulin sensitivity and mitochondrial function in severely burned children* , 2010, Critical care medicine.

[3]  M. Rigby,et al.  A disparity between physician attitudes and practice regarding hyperglycemia in pediatric intensive care units in the United States: a survey on actual practice habits , 2010, Critical care.

[4]  Miet Schetz,et al.  Intensive Insulin Therapy in Critically Ill Patients: NICE-SUGAR or Leuven Blood Glucose Target? , 2009 .

[5]  Stephane Heritier,et al.  Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.

[6]  Greet Van den Berghe,et al.  Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study , 2009, The Lancet.

[7]  Kiran B. Hebbar,et al.  Neuroendocrine dysfunction in pediatric critical illness* , 2009, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[8]  J. L. Messina,et al.  Crosstalk between growth hormone and insulin signaling. , 2009, Vitamins and hormones.

[9]  Christopher R Palmer,et al.  Early insulin therapy in very-low-birth-weight infants. , 2008, The New England journal of medicine.

[10]  M. Ranke,et al.  Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. , 2008, The Journal of clinical endocrinology and metabolism.

[11]  G. Van den Berghe,et al.  Effect of intensive insulin therapy on insulin sensitivity in the critically ill. , 2007, The Journal of clinical endocrinology and metabolism.

[12]  D. Clemmons IGF-I assays: current assay methodologies and their limitations , 2007, Pituitary.

[13]  G. Van den Berghe,et al.  Changes within the growth hormone/insulin-like growth factor I/IGF binding protein axis during critical illness. , 2006, Endocrinology and metabolism clinics of North America.

[14]  G. Van den Berghe,et al.  Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.

[15]  A. Dona,et al.  Activity of the Growth Hormone/Insulin-like Growth Factor-I Axis in Critically Ill Children , 2005, Journal of pediatric endocrinology & metabolism : JPEM.

[16]  J. Frystyk,et al.  Residual β-Cell Function More than Glycemic Control Determines Abnormalities of the Insulin-Like Growth Factor System in Type 1 Diabetes , 2004 .

[17]  G. Van den Berghe,et al.  Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. , 2004, The Journal of clinical endocrinology and metabolism.

[18]  H. Orskov,et al.  A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. , 2003, American journal of physiology. Endocrinology and metabolism.

[19]  G. Van den Berghe,et al.  Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. , 2002, The Journal of clinical endocrinology and metabolism.

[20]  W. Hop,et al.  Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  R. Baxter,et al.  Changes in the IGF-IGFBP axis in critical illness. , 2001, Best practice & research. Clinical endocrinology & metabolism.

[22]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[23]  M. Fisberg,et al.  The role of insulin-like growth factor I, growth hormone, and plasma proteins in surgical outcome of children with congenital heart disease , 2001, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[24]  N R Webster,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.

[25]  G. Van den Berghe,et al.  Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.

[26]  R. Baxter,et al.  Thrity-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients , 1998 .

[27]  G. Van den Berghe,et al.  Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  R. Ross,et al.  The role of IGFs in catabolism. , 1997, Bailliere's clinical endocrinology and metabolism.

[29]  B. Tönshoff,et al.  Insulin-like growth factors (IGFs) and IGF binding proteins, serum acid-labile subunit and growth hormone binding protein in nephrotic children. , 1997, Kidney international.

[30]  C. Hinds,et al.  Growth hormone and insulin- like growth factors in critical illness , 1997, Intensive Care Medicine.

[31]  M. Tauber,et al.  Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM , 1996, Diabetologia.

[32]  P. Hindmarsh,et al.  An assessment of growth hormone provocation tests. , 1995, Archives of disease in childhood.

[33]  J. Wahren,et al.  Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. , 1994, The Journal of clinical endocrinology and metabolism.

[34]  M. Binoux,et al.  In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. , 1994, The Journal of clinical investigation.

[35]  O. Ljungqvist,et al.  Development of postoperative insulin resistance is associated with the magnitude of operation. , 1993, The European journal of surgery = Acta chirurgica.

[36]  S. Amiel,et al.  Suppression of endogenous insulin secretion regulates the rapid rise of insulin‐like growth factor binding protein (IGFBP)‐1 levels following acute hypoglycaemia , 1993, Clinical endocrinology.

[37]  R. Baxter,et al.  Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. , 1990, The Journal of clinical endocrinology and metabolism.

[38]  R. Baxter,et al.  Regulation of growth hormone-independent insulin-like growth factor-binding protein (BP-28) in cultured human fetal liver explants. , 1989, The Journal of clinical endocrinology and metabolism.

[39]  M. Seppälä,et al.  Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. , 1988, The Journal of clinical endocrinology and metabolism.

[40]  R. Baxter,et al.  Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. , 1986, The Journal of clinical investigation.

[41]  R. Wolfe,et al.  Mechanisms of Insulin Resistance Following Injury , 1982, Annals of surgery.

[42]  T. Brown,et al.  Fasting plasma glucose in children , 1980, Australian paediatric journal.

[43]  R. Baxter,et al.  Regulation of hepatic growth hormone receptors by insulin. , 1978, Biochemical and biophysical research communications.

[44]  L. Phillips,et al.  The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver. , 1976, Endocrinology.